Mather Group LLC. Sells 2,070 Shares of Danaher Corporation $DHR

Key Points

• Mather Group LLC has reduced its stake in Danaher Corporation by 65.0%, selling 2,070 shares to end with 1,114 shares valued at $220,000 as of the latest reporting period.
• Danaher reported a quarterly earnings per share (EPS) of $1.80, surpassing analysts' expectations of $1.64, with revenue reaching $5.94 billion, up 3.4% compared to the same quarter last year.
• The company declared a quarterly dividend of $0.32 per share, with an annualized dividend yield of 0.7%, set to be paid on October 31st to investors of record as of September 26th.

Mather Group LLC. lowered its stake in Danaher Corporation (NYSE:DHR - Free Report) by 65.0% in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,114 shares of the conglomerate's stock after selling 2,070 shares during the quarter. Mather Group LLC.'s holdings in Danaher were worth $220,000 at the end of the most recent reporting period.

Other hedge funds also recently modified their holdings of the company. MGO One Seven LLC increased its stake in shares of Danaher by 485.7% in the 1st quarter. MGO One Seven LLC now owns 25,098 shares of the conglomerate's stock valued at $5,145,000 after acquiring an additional 20,813 shares in the last quarter. UniSuper Management Pty Ltd grew its position in Danaher by 1.6% in the 1st quarter. UniSuper Management Pty Ltd now owns 170,505 shares of the conglomerate's stock valued at $34,954,000 after purchasing an additional 2,667 shares during the period. Asahi Life Asset Management CO. LTD. acquired a new stake in Danaher in the 1st quarter valued at $539,000. Horizon Financial Services LLC grew its position in Danaher by 20,400.0% in the 1st quarter. Horizon Financial Services LLC now owns 8,200 shares of the conglomerate's stock valued at $1,681,000 after purchasing an additional 8,160 shares during the period. Finally, Cooper Investors PTY Ltd. grew its position in Danaher by 4.9% in the 2nd quarter. Cooper Investors PTY Ltd. now owns 37,435 shares of the conglomerate's stock valued at $7,395,000 after purchasing an additional 1,736 shares during the period. Institutional investors own 79.05% of the company's stock.

Danaher Price Performance

DHR opened at $184.97 on Friday. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.62 and a quick ratio of 1.22. The company has a market capitalization of $132.45 billion, a price-to-earnings ratio of 39.36, a P/E/G ratio of 2.63 and a beta of 0.75. The firm's fifty day moving average price is $199.44 and its two-hundred day moving average price is $197.53. Danaher Corporation has a 1 year low of $171.00 and a 1 year high of $279.59.

Danaher (NYSE:DHR - Get Free Report) last posted its quarterly earnings data on Tuesday, July 22nd. The conglomerate reported $1.80 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.64 by $0.16. The firm had revenue of $5.94 billion for the quarter, compared to the consensus estimate of $5.83 billion. Danaher had a net margin of 14.21% and a return on equity of 10.70%. The business's revenue for the quarter was up 3.4% compared to the same quarter last year. During the same period in the previous year, the firm earned $1.72 EPS. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. As a group, analysts anticipate that Danaher Corporation will post 7.63 earnings per share for the current fiscal year.

Danaher Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, October 31st. Investors of record on Friday, September 26th will be issued a $0.32 dividend. This represents a $1.28 dividend on an annualized basis and a dividend yield of 0.7%. The ex-dividend date of this dividend is Friday, September 26th. Danaher's payout ratio is 27.23%.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on DHR. Guggenheim reissued a "buy" rating and issued a $250.00 price target on shares of Danaher in a research report on Wednesday, July 23rd. Deutsche Bank Aktiengesellschaft reduced their price target on shares of Danaher from $240.00 to $235.00 in a research report on Thursday, June 5th. Evercore ISI reduced their price target on shares of Danaher from $230.00 to $226.00 and set an "outperform" rating for the company in a research report on Tuesday, July 8th. Scotiabank raised shares of Danaher from a "sector perform" rating to a "sector outperform" rating and set a $275.00 price target for the company in a research report on Friday, July 11th. Finally, Barclays reissued an "overweight" rating and issued a $225.00 price target (up previously from $215.00) on shares of Danaher in a research report on Tuesday, June 24th. Seventeen analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $245.91.

Insider Buying and Selling at Danaher

In related news, Director Teri List sold 2,778 shares of the business's stock in a transaction dated Friday, August 22nd. The shares were sold at an average price of $211.06, for a total value of $586,324.68. Following the transaction, the director directly owned 20,751 shares of the company's stock, valued at approximately $4,379,706.06. The trade was a 11.81% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 11.10% of the company's stock.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.

Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Corporation (NYSE:DHR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.